Krsnaa Diagnostics Limited has informed the Exchange that Board of Directors at its meeting held on May 25, 2026, recommended Final Dividend of Rs. 2 per equity share.
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krsnaa Diagnostics reported audited standalone PAT of Rs. 1,026.75 million (up ~24%) and consolidated PAT of Rs. 1,014.31 million (up ~30.7%) for FY 2025-26. Standalone revenue was Rs. 6,909.47 million (flat YoY at +1.4%), while consolidated revenue rose 7.8% to Rs. 7,727.74 million. EBITDA margins expanded by ~3.1 percentage points YoY to ~32% on standalone basis. The Board recommended a final dividend of Rs. 2 per share (40% face value), subject to shareholder approval. Key risk noted: Income Tax authorities raised a total demand of Rs. 626.90 million across multiple assessment years (AY 2017-18 to AY 2019-20) for alleged undisclosed income and disallowed deductions. The Company has filed appeals and deposited Rs. 102.77 million under protest. Statutory auditors issued an unmodified opinion with an Emphasis of Matter on the tax matter. Borrowings surged significantly (non-current borrowings jumped from Rs. 185 million to Rs. 4,371 million), partly due to debenture issuance of Rs. 4,174 million. A fair value gain of Rs. 258.75 million was recognized on derecognition of associate Apulki Healthcare. New statutory auditor M/s Kirtane & Pandit LLP appointed for FY 2026-27 to 2030-31.
The company delivered strong PAT growth (~30%) and margin expansion, with an unmodified audit opinion providing comfort. However, the Rs. 626.90 million tax demand remains a contingent liability risk, and the large increase in borrowings raises leverage concerns. The dividend is positive for shareholder returns.